FDMT. – 4D Molecular Therapeutics Inc
Float Short %
10.2
Margin Of Safety %
Put/Call OI Ratio
0.2
EPS Next Q Diff
-1.62
EPS Last/This Y
-0.28
EPS This/Next Y
-0.22
Price
11.08
Target Price
31.62
Analyst Recom
1.5
Performance Q
58.97
Relative Volume
1.13
Beta
2.95
Ticker: FDMT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | FDMT | 10.16 | 0.38 | 6.05 | 5265 |
| 2025-11-11 | FDMT | 10.8 | 0.44 | 0.14 | 5498 |
| 2025-11-12 | FDMT | 10.98 | 0.43 | 0.04 | 5506 |
| 2025-11-13 | FDMT | 10.27 | 0.43 | 0.00 | 5511 |
| 2025-11-14 | FDMT | 10.78 | 0.43 | 0.01 | 5559 |
| 2025-11-17 | FDMT | 10.95 | 0.43 | 0.29 | 5534 |
| 2025-11-18 | FDMT | 10.08 | 0.44 | 0.01 | 5500 |
| 2025-11-19 | FDMT | 10.81 | 0.44 | 0.25 | 5545 |
| 2025-11-20 | FDMT | 10.33 | 0.44 | 0.10 | 5547 |
| 2025-11-21 | FDMT | 10.84 | 0.45 | 0.02 | 5529 |
| 2025-11-24 | FDMT | 10.88 | 0.11 | 0.07 | 3149 |
| 2025-11-25 | FDMT | 10.68 | 0.11 | 2.35 | 3167 |
| 2025-11-26 | FDMT | 11 | 0.15 | 0.15 | 3341 |
| 2025-12-01 | FDMT | 10.51 | 0.14 | 5.83 | 3505 |
| 2025-12-02 | FDMT | 10.12 | 0.20 | 0.00 | 3689 |
| 2025-12-03 | FDMT | 10.68 | 0.20 | 1.82 | 3731 |
| 2025-12-04 | FDMT | 11.2 | 0.20 | 0.00 | 3738 |
| 2025-12-05 | FDMT | 10.69 | 0.20 | 0.02 | 3792 |
| 2025-12-08 | FDMT | 11.1 | 0.20 | 0.02 | 3757 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | FDMT | 10.17 | -24.6 | - | -3.67 |
| 2025-11-11 | FDMT | 10.80 | -24.6 | - | -3.67 |
| 2025-11-12 | FDMT | 10.97 | -24.6 | - | -3.67 |
| 2025-11-13 | FDMT | 10.27 | -24.6 | - | -3.67 |
| 2025-11-14 | FDMT | 10.78 | 30.8 | - | -3.43 |
| 2025-11-17 | FDMT | 10.96 | 40.9 | - | -3.26 |
| 2025-11-18 | FDMT | 10.06 | 40.9 | - | -3.26 |
| 2025-11-19 | FDMT | 10.80 | 40.9 | - | -3.26 |
| 2025-11-20 | FDMT | 10.32 | 40.9 | - | -3.26 |
| 2025-11-21 | FDMT | 10.84 | 41.3 | - | -3.26 |
| 2025-11-24 | FDMT | 10.88 | 41.3 | - | -3.26 |
| 2025-11-25 | FDMT | 10.68 | 41.3 | - | -3.26 |
| 2025-11-26 | FDMT | 11.00 | 41.3 | - | -3.26 |
| 2025-12-01 | FDMT | 10.50 | 41.3 | - | -3.26 |
| 2025-12-02 | FDMT | 10.13 | 41.3 | - | -3.26 |
| 2025-12-03 | FDMT | 10.70 | 41.3 | - | -3.26 |
| 2025-12-04 | FDMT | 11.21 | 41.3 | - | -3.26 |
| 2025-12-05 | FDMT | 10.70 | 41.3 | - | -3.26 |
| 2025-12-08 | FDMT | 11.08 | 41.3 | - | -3.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | FDMT | -0.17 | -8.89 | 10.19 |
| 2025-11-11 | FDMT | -0.17 | -8.89 | 10.19 |
| 2025-11-12 | FDMT | -0.17 | -8.89 | 10.32 |
| 2025-11-13 | FDMT | -0.14 | -8.89 | 0 |
| 2025-11-14 | FDMT | -0.14 | -8.89 | 8.44 |
| 2025-11-17 | FDMT | -0.14 | -4.35 | 8.43 |
| 2025-11-18 | FDMT | -0.14 | -4.35 | 8.43 |
| 2025-11-19 | FDMT | -0.14 | -4.35 | 8.43 |
| 2025-11-20 | FDMT | -0.17 | -4.35 | 8.40 |
| 2025-11-21 | FDMT | -0.17 | -4.35 | 8.40 |
| 2025-11-24 | FDMT | -0.17 | -1.55 | 8.40 |
| 2025-11-25 | FDMT | -0.17 | -1.55 | 8.40 |
| 2025-11-26 | FDMT | -0.17 | -1.55 | 10.20 |
| 2025-12-01 | FDMT | -0.17 | -1.52 | 10.20 |
| 2025-12-02 | FDMT | -0.17 | -1.52 | 10.20 |
| 2025-12-03 | FDMT | -0.17 | -1.52 | 10.20 |
| 2025-12-04 | FDMT | -0.17 | -1.52 | 10.20 |
| 2025-12-05 | FDMT | -0.17 | -1.52 | 10.20 |
| 2025-12-08 | FDMT | -0.17 | -1.52 | 10.20 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.69
Avg. EPS Est. Current Quarter
-0.53
Avg. EPS Est. Next Quarter
-0.93
Insider Transactions
-0.17
Institutional Transactions
-1.52
Beta
2.95
Average Sales Estimate Current Quarter
29
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
16
Growth Score
23
Sentiment Score
15
Actual DrawDown %
79.9
Max Drawdown 5-Year %
Target Price
31.62
P/E
Forward P/E
PEG
P/S
5275.51
P/B
1.4
P/Free Cash Flow
EPS
-3.94
Average EPS Est. Cur. Y
-3.26
EPS Next Y. (Est.)
-3.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-174314.17
Relative Volume
1.13
Return on Equity vs Sector %
-83.6
Return on Equity vs Industry %
-68.7
EPS 1 7Days Diff
0.4
EPS 1 30Days Diff
0.42
EBIT Estimation
4D Molecular Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 227
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading